1280 Results for "

PD

" in MedChemExpress (MCE) Product Catalog:
Products (1280)

1280 Results for "PD" in MCE Product Catalog:

438
438 Publications Verification
Art. -Nr.: HY-B0988
CAS. Nr.: 138-14-7
Synonyms: Desferrioxamine B mesylate; DFOM
Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .
loading...
    loading...
438
438 Publications Verification
Art. -Nr.: HY-B1625
CAS. Nr.: 70-51-9
Synonyms: Deferoxamine B; Deferriferrioxamine B; Deferrioxamine
Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulates HIF-1α levels with good antioxidant activity. Deferoxamine also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .
loading...
    loading...
407
407 Cited Publications
Art. -Nr.: HY-12028
CAS. Nr.: 167869-21-8
Reinheit:  98.89%
Forschungsgebiete:  

Cancer

PD98059 is a potent and selective MEK inhibitor with an IC50 of 5 µM. PD98059 binds to the inactive form of MEK, thereby preventing the activation of MEK1 (IC50 of 2-7 µM) and MEK2 (IC50 of 50 µM) by upstream kinases. PD98059 is a ERK1/2 signaling inhibitor. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR), and suppresses TCDD binding (IC50 of 4 μM) and AHR transformation (IC50 of 1 μM). PD98059 also inhibits Mycobacterium bovis Bacillus CalmetteGuerin (BCG)-induced autophagy .
loading...
    loading...
249
249 Cited Publications
Art. -Nr.: HY-50767
CAS. Nr.: 571190-30-2
Synonyms: PD 0332991
Target:  

CDK

Forschungsgebiete:  

Cancer

Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
loading...
    loading...
249
249 Cited Publications
Art. -Nr.: HY-50767A
CAS. Nr.: 827022-32-2
Synonyms: PD 0332991 monohydrochloride
Target:  

CDK

Forschungsgebiete:  

Cancer

Palbociclib (PD 0332991) monohydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib monohydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
loading...
    loading...
245
245 Cited Publications
Art. -Nr.: HY-A0065
CAS. Nr.: 827022-33-3
Synonyms: PD 0332991 isethionate
Target:  

CDK

Forschungsgebiete:  

Infection Neurological Disease Cancer

Palbociclib (PD 0332991) isethionate is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib isethionate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
loading...
    loading...
229
229 Cited Publications
Art. -Nr.: HY-50767C
CAS. Nr.: 571189-11-2
Synonyms: PD-0332991 hydrochloride
Target:  

CDK

Forschungsgebiete:  

Cancer

Palbociclib (PD 0332991) hydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib hydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib hydrochloride can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
loading...
    loading...
188
188 Cited Publications
Art. -Nr.: HY-D0079
CAS. Nr.: 104821-25-2
Synonyms: Hydroethidine; PD-MY 003
Dihydroethidium, also known as DHE, is a peroxide indicator. Dihydroethidium penetrates cell membranes to form a fluorescent protein complex with blue fluoresces. After entering the cells, Dihydroethidium is mainly localized in the cell membrane, cytoplasm and nucleus, and the staining effect is the strongest in the nucleus. Dihydroethidium produces inherent blue fluorescence with a maximum excitation wavelength of 370 nm and a maximum emission wavelength of 420 nm; after dehydrogenation, Dihydroethidium combines with RNA or DNA to produce red fluorescence with a maximum excitation wavelength of 300 nm and a maximum emission wavelength of 610 nm. 535 nm can also be used as the excitation wavelength for actual observation .
loading...
    loading...
159
159 Cited Publications
Art. -Nr.: HY-10254
CAS. Nr.: 391210-10-9
Reinheit:  99.95%
Synonyms: PD0325901; PD325901
Target:  

MEK Autophagy Apoptosis

Forschungsgebiete:  

Cancer

Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive MEK inhibitor with an IC50 of 0.33 nM. Mirdametinib exhibits a Ki app of 1 nM against activated MEK1 and MEK2. Mirdametinib suppresses the expression of p-ERK1/2 and induces apoptosis. Mirdametinib has anti-cancer activity for a broad spectrum of human tumor xenografts .
loading...
    loading...
74
74 Cited Publications
Art. -Nr.: HY-16141
CAS. Nr.: 188968-51-6
Synonyms: EMD 121974
Cilengitide (EMD 121974) is a BBB-permeable integrins antagonist with IC50s of 0.61 nM (ανβ3), 8.4 nM (ανβ5) and 14.9 nM (α5β1), respectively. Cilengitide inhibits the binding of ανβ3 and ανβ5 to Vitronectin with IC50s of 4 nM and 79 nM, respectively. Cilengitide inhibits TGF-β/Smad signaling, mediates PD-L1 expression. Cilengitide also induces apoptosis, shows antiangiogenic effect in the research against glioblastoma and other cancers .
loading...
    loading...
50
50 Cited Publications
Art. -Nr.: HY-10617A
CAS. Nr.: 283173-50-2
Reinheit:  99.97%
Synonyms: AG014699; PF-01367338
Target:  

PARP

Forschungsgebiete:  

Cancer

Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research .
loading...
    loading...
49
49 Cited Publications
Art. -Nr.: HY-10617
CAS. Nr.: 459868-92-9
Reinheit:  99.56%
Synonyms: AG-014699 phosphate; PF-01367338 phosphate
Target:  

PARP

Forschungsgebiete:  

Cancer

Rucaparib (AG014699) phosphate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib phosphate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib phosphate has the potential for castration-resistant prostate cancer (CRPC) research .
loading...
    loading...
49
49 Cited Publications
Art. -Nr.: HY-B1081
CAS. Nr.: 28094-15-7
Synonyms: 6-Hydroxydopamine Hydrochloride
Oxidopamine (6-OHDA) hydrochloride is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrochloride is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrochloride promotes COX-2 activation, leading to PGE2 synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrochloride can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome .
loading...
    loading...
49
49 Cited Publications
Art. -Nr.: HY-B1081A
CAS. Nr.: 636-00-0
Synonyms: 6-Hydroxydopamine hydrobromide; 6-OHDA hydrobromide
Oxidopamine (6-OHDA) hydrobromide is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrobromide is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrobromide promotes COX-2 activation, leading to PGE2 synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrobromide can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome .
loading...
    loading...
41
41 Cited Publications
Art. -Nr.: HY-102003
CAS. Nr.: 1859053-21-6
Reinheit:  99.82%
Synonyms: AG014699 monocamsylate; PF-01367338 monocamsylate
Target:  

PARP

Forschungsgebiete:  

Cancer

Rucaparib (AG014699) monocamsylate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib monocamsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib monocamsylate has the potential for castration-resistant prostate cancer (CRPC) research .
loading...
    loading...
40
40 Cited Publications
Art. -Nr.: HY-P9904
CAS. Nr.: 1380723-44-3
Synonyms: MPDL3280A; RG-7446; RO-5541267

Forschungsgebiete:  

Cancer

Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
loading...
    loading...
35
35 Cited Publications
Art. -Nr.: HY-P9902A
Synonyms: MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)

Target:  

PD-1/PD-L1

Forschungsgebiete:  

Cancer

Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1 .
loading...
    loading...
35
35 Cited Publications
Art. -Nr.: HY-P9902
CAS. Nr.: 1374853-91-4
Synonyms: MK-3475; Lambrolizumab

Target:  

PD-1/PD-L1

Forschungsgebiete:  

Cancer

Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
loading...
    loading...
35
35 Cited Publications
Art. -Nr.: HY-136927
CAS. Nr.: 129425-81-6
Reinheit:  99.81%
Target:  

STING

Forschungsgebiete:  

Inflammation/Immunology Cancer

MSA-2, a potent and orally available non-nucleotide STING agonist, is bound to STING as a noncovalent dimer with nanomolar affinity. MSA-2 shows EC50s of 8.3 and 24 μM for human STING isoforms WT and HAQ, respectively. MSA-2 stimulates interferon-β secretion in tumors, induces tumor regression with durable antitumor immunity, and synergizes with anti-PD-1 in syngeneic mouse tumor models .
loading...
    loading...
32
32 Cited Publications
Art. -Nr.: HY-19991
CAS. Nr.: 1675201-83-8
Synonyms: PD-1/PD-L1 inhibitor 1
Target:  

PD-1/PD-L1 Apoptosis

Forschungsgebiete:  

Inflammation/Immunology Cancer

BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM) .
loading...
    loading...